Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18068091 | 0.79 | KCNK3 (0.35) | P2RX3P2RX2KCNK3KCNK9 | |
| SCHEMBL21076511 | 0.77 | KCNK3 (0.33) | P2RX3P2RX2AAK1KCNK3KCNK9 | |
| SCHEMBL21010496 | 0.76 | AR (0.37) | AAK1RXRAGRIN1GRIN2B | |
| SCHEMBL21076633 | 0.75 | KCNK3 (0.33) | P2RX3P2RX2KCNK3KCNK9PGK1 | |
| SCHEMBL20642453 | 0.73 | TLR9 (0.36) | P2RX3P2RX2RXRAGRIN1GRIN2B | |
| SCHEMBL20642400 | 0.72 | P2RX3 (0.35) | P2RX3P2RX2AAK1KCNK3KCNK9 | |
| SCHEMBL20642322 | 0.71 | NOS3 (0.33) | AAK1 | |
| SCHEMBL20642297 | 0.69 | LMNA (0.32) | P2RX3P2RX2 | |
| SCHEMBL25795554 | 0.69 | LMNA (0.36) | — | |
| SCHEMBL15417381 | 0.69 | NOS3 (0.38) | AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695348-B2 | Sulfonyl pyridyl TRP inhibitors | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190167681-A1 | SULFONYL PYRIDYL TRP INHIBITORS | GENENTECH, INC. (US) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695348-B2 | Sulfonyl pyridyl TRP inhibitors | TRPA1, TRPV1, TRPV5 | P2RX3 13/4885P2RX2 25/4885AAK1 1156/4885 |
| US-20190167681-A1 | SULFONYL PYRIDYL TRP INHIBITORS | TRPA1, TRPV1, TRPV5 | P2RX3 13/4885P2RX2 25/4885AAK1 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.